Clinical Trial Facilitation Group (CTFG)



The Heads of Medicines Agencies (HMA) agreed in 2004 to establish a clinical trials facilitation group (CTFG) to coordinate the implementation of the EU clinical trials directive 2001/20 EC across the member states.

In relation to clincial trials the CTFG acts as a forum for discussion to agree on common principles and processes to be applied throughout the European medicines regulatory network (EMRN). It also promotes harmonisation of clinical trial assessment decisions and administrative processes across the national competent authorities (NCAs).


CTFG workshop on new complex clinical trial design -  22.03.2018 Rome, Italy | pdf

Members and Representatives

Members and representatives

  • Representatives from the national competent authorities for the authorisation of clinical trials on human subjects, the European Commission and the European Medicines Agency
  • Representatives from other interested parties may be invited to attend the CTFG meetings on an ad hoc basis if deemed valuable and consensual and in agreement with the HMA rules on
  • The Chair is elected amongst the members for a period of two years
  • Currently chaired jointly by two Co-chairs: Elke Stahl, Ph.D (BfArM, Germany) and Ann Marie Janson Lang, MD, Ph.D (MPA, Sweden)
  • The mentor of the group at the level of HMA is Xavier De Cuyper (FAMHP, Belgium)



The secretariat of the group is shared by Ireland and Italy. The HMA contact is Massimiliano Sarra, PhD, from the Italian Medicine Agency (AIFA)


Activities and achievements

Activities and achievements

  • Stakeholder information: HMA VHP for clinical trials - 1000th procedure
  • Publication of updated Q&A documents e.g. on follow-up of patients after clinical trials, DSUR reporting.
  • Enlargement of the Voluntary Harmonisation Procedure in the number of initial applications, substantial amendments and distribution of Sponsors (worldwide: EU;USA, Canada, Australia, Singapore).
  • Liaising between the EMA, CHMP and CTFG on specific topics where the decision on a marketing authorisation has an impact on clinical trials in Europe.
  • Continuation of work sharing e.g. DSUR, exchange of opinions or assessment on critical topics/ national Clinical Trial Applications.
  • Supporting and analysing the new Clinical Trials Regulation

Key documents list

News and events